Last reviewed · How we verify

NCT03942835: CAT

Psychometric Validation of the Competitive Attention Test

Terminated NA Last updated 1 November 2021
What this trial tests

NA trial testing experience 1 : Competitive attention test in healthy participants in Attention Deficit Hyperactivity Disorder in 26 participants. Terminated before completion.

Timeline
21 January 2020
Primary endpoint
20 March 2021
20 April 2021

Quick facts

Lead sponsorHospices Civils de Lyon
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment26
Start date21 January 2020
Primary completion20 March 2021
Estimated completion20 April 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 6 to 90, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims at validating a new neuropsychological test to measure voluntary and involuntary attention for clinical use to diagnose attentional deficits. This project proposes: * a test-retest procedure in healthy subjects aged from 6 to 90 year-old; * testing in attention deficit hyperactivity disorder (ADHD) patients before psychostimulant treatment; * testing in attention deficit hyperactivity disorder (ADHD) patients before psychostimulant treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing